AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00029-07v1
51/7/2621    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, T. A.
Right arrow Articles by Bush, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, T. A.
Right arrow Articles by Bush, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2007, p. 2621-2624, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00029-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae{triangledown}

Todd A. Davies,1* Malcolm G. P. Page,2 Wenchi Shang,1 Ted Andrew,1 Malgosia Kania,2 and Karen Bush1

Johnson & Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey,1 Basilea Pharmaceutica AG, Grenzacherstrasse 487, P.O. Box CH-4005, Basel, Switzerland2

Received 10 January 2007/ Returned for modification 15 February 2007/ Accepted 19 April 2007

Ceftobiprole exhibited tight binding to PBP2a in methicillin-resistant Staphylococcus aureus, PBP2x in penicillin-resistant Streptococcus pneumoniae, and PBP3 and other essential penicillin-binding proteins in methicillin-susceptible S. aureus, Escherichia coli, and Pseudomonas aeruginosa. Ceftobiprole also bound well to PBP2 in the latter organisms, contributing to the broad-spectrum antibacterial activity against gram-negative and gram-positive bacteria.

* Corresponding author. Mailing address: Johnson & Johnson Pharmaceutical Research and Development, LLC, Room B225, 1000 Route 202, Raritan, NJ 08869. Phone: (908) 707-3465. Fax: (908) 707-3501. E-mail: tdavies{at}prdus.jnj.com

{triangledown} Published ahead of print on 30 April 2007.

Antimicrobial Agents and Chemotherapy, July 2007, p. 2621-2624, Vol. 51, No. 7
0066-4804/07/$08.00+0     doi:10.1128/AAC.00029-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.